Technical Analysis for CLRB - Cellectar Biosciences, Inc.

Grade Last Price % Change Price Change
F 1.4 0.72% 0.01
CLRB closed up 0.72 percent on Tuesday, April 13, 2021, on 25 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.
Earnings due: May 5
*** please verify all earnings dates ***

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical CLRB trend table...

Date Alert Name Type % Chg
Narrow Range Bar Range Contraction 0.00%
NR7 Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Wide Bands Range Expansion 0.72%
Down 3 Days in a Row Weakness 0.72%
Oversold Stochastic Weakness 0.72%
Wide Bands Range Expansion -5.41%
Oversold Stochastic Weakness -5.41%
Narrow Range Bar Range Contraction -9.09%
Older End-of-Day Signals for CLRB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 3% about 21 hours ago
Up 2% about 21 hours ago
Up 1% about 21 hours ago
Fell Below Previous Day's Low about 21 hours ago
Down 5% 2 days ago
View Earlier Intraday Alerts

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Cellectar Biosciences, Inc. Description

Cellectar Biosciences, Inc., a development stage biopharmaceutical company, develops compounds for the treatment and imaging of cancer. Its proprietary product candidates include I-124-CLR1404, a small-molecule, broad-spectrum, and cancer-targeting positron emission tomography (PET) imaging agent that is in Phase II clinical trial for glioblastoma, as well as in Phase I/II clinical trials for approximately 11 solid tumor indications; and CLR1502, a preclinical, cancer-targeted, and non-radioactive optical imaging agent for intraoperative tumor margin illumination and non-invasive tumor imaging. The company also develops I-131-CLR1404, a small-molecule, broad-spectrum, and cancer-targeted molecular radiotherapeutic that delivers cytotoxic radiation directly and selectively to cancer cells and cancer stem cells, as well as is in Phase Ib dose-escalation trial for patients with advanced solid tumors; and CLR1404, a cancer-targeted chemotherapy. The company was formerly known as Novelos Therapeutics, Inc. and changed its name to Cellectar Biosciences, Inc. in February 2014. Cellectar Biosciences, Inc. was founded in 2002 and is headquartered in Madison, Wisconsin.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Cancer Clinical Medicine Solid Tumors Oncology Imaging Stem Cells Chemotherapy Radiation Occupational Safety And Health Blastoma Antineoplastic Drugs Glioblastoma Radiation Therapy Targeted Therapy Advanced Solid Tumors Tomography Solid Tumor Imaging Agent Positron Emission Tomography Cancer Stem Cell Cancer Stem Cells

Is CLRB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 2.97
52 Week Low 1.01
Average Volume 1,784,468
200-Day Moving Average 1.60
50-Day Moving Average 1.92
20-Day Moving Average 1.66
10-Day Moving Average 1.54
Average True Range 0.13
ADX 18.21
+DI 16.12
-DI 29.98
Chandelier Exit (Long, 3 ATRs ) 1.74
Chandelier Exit (Short, 3 ATRs ) 1.76
Upper Bollinger Band 2.02
Lower Bollinger Band 1.31
Percent B (%b) 0.13
BandWidth 42.80
MACD Line -0.13
MACD Signal Line -0.11
MACD Histogram -0.0154
Fundamentals Value
Market Cap 37.54 Million
Num Shares 26.8 Million
EPS -3.13
Price-to-Earnings (P/E) Ratio -0.45
Price-to-Sales 0.00
Price-to-Book 2.69
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 1.49
Resistance 3 (R3) 1.49 1.47 1.47
Resistance 2 (R2) 1.47 1.44 1.46 1.47
Resistance 1 (R1) 1.43 1.43 1.42 1.43 1.46
Pivot Point 1.41 1.41 1.40 1.40 1.41
Support 1 (S1) 1.37 1.38 1.36 1.37 1.34
Support 2 (S2) 1.35 1.37 1.35 1.33
Support 3 (S3) 1.31 1.35 1.33
Support 4 (S4) 1.31